2025-09-042025-09-042024Fisman, D., Giglio, N., Levin, M. J., Nguyen, V. H., Pelton, S. I., Postma, M., Ruiz-Aragón, J., Urueña, A., & Mould-Quevedo, J. F. (2024). The economic rationale for cell-based influenza vaccines in children and adults: A review of cost-effectiveness analyses. Human Vaccines & Immunotherapeutics,20(1),2164-5515HUMANVACCINES_20(1)https://doi.org/10.1080/21645515.2024.2351675https://www.tandfonline.com/doi/pdf/10.1080/21645515.2024.2351675?needAccess=truehttp://rid.isalud.edu.ar/handle/1/2163Fil: Urueña, Analía. Universidad ISALUD. Centro de Estudios para la Prevencion y Control de Enfermedades Transmisibles (CEPyCET)Seasonal influenza significantly affects both health and economic costs in children and adults. This narrative review summarizes published cost-effectiveness analyses (CEAs) of cell-based influenza vaccines in children and adults <65 years of age, critically assesses the assumptions and approaches used in these analyses, and considers the role of cell-based influenza vaccines for children and adults. CEAs from multiple countries demonstrated the cost-effectiveness of cell-based quadrivalent influenza vaccines (QIVc) compared with egg-based trivalent/quadrivalent influenza vaccines (TIVe/QIVe). CEA findings were consistent across models relying on different relative vaccine effectiveness (rVE) estimate inputs, with the rVE of QIVc versus QIVe ranging from 8.1% to 36.2% in favor of QIVc. Across multiple scenarios and types of analyses, QIVc was consistently cost-effective compared with QIVe, including in children and adults across different regions of the world.enCC BY-NC-ND 4.0INFLUENZACOST-EFFECTIVENESS ANALYSISCELL-BASED INFLUENZAVACCINEINFLUENZAANÁLISIS COSTO EFECTIVIDADVACUNASArtículohttps://orcid.org/0000-0001-5108-2534